Anna Stanhewicz, PhD

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Anna Stanhewicz, PhD sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).

14 total trials 10 currently recruiting 3 completed early-phase tilt top decile by trial count

Anna Stanhewicz, PhD: 14 sponsored US clinical trials, 10 recruiting.

Anna Stanhewicz, PhD sponsors 14 registered US clinical trials on ClinicalTrials.gov, 10 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gestational Diabetes, with 4 trials.

Top-decile sponsor footprint

Anna Stanhewicz, PhD ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

14 total, page 1 of 1

RECRUITING Phase 1

The Impact of Gestational Diabetes Mellitus on Cerebral Blood Flow and Cerebrovascular Function After Pregnancy

NCT06911372
RECRUITING Early Phase 1

Vascular Effects of High-Salt After Preeclampsia

NCT06749418
RECRUITING Early Phase 1

Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM

NCT06547619
RECRUITING Early Phase 1

Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes

NCT05917587
RECRUITING Early Phase 1

Sex Differences in the Vascular Effects of E-cigarette Use

NCT06159608
RECRUITING Early Phase 1

Daily Aspirin Treatment After Preeclampsia

NCT06168461
RECRUITING Early Phase 1

Role of NADPH Oxidase in Microvascular Dysfunction Following GDM

NCT05946798
RECRUITING Early Phase 1

Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes

NCT05946785
RECRUITING Early Phase 1

Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia

NCT05937841
RECRUITING Early Phase 1

Prenatal Aspirin and Postpartum Vascular Function

NCT05653973
ACTIVE NOT RECRUITING Early Phase 1

MR and Inflammation After Preeclampsia

NCT07345845
COMPLETED Early Phase 1

Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia

NCT06157580
COMPLETED Early Phase 1

Sex Differences in the Dilatory Response of Compound 21

NCT05576155
COMPLETED Early Phase 1

Losartan for Improved Vascular Endothelial Function After Preeclampsia

NCT04632589

Phase Distribution

PhaseTrial count
Phase 1 14

Therapeutic Areas

Gestational Diabetes 4
Preeclampsia 4
Preeclampsia Postpartum 3
Vascular Endothelial Function 2
Sex Differences 1
Uncomplicated Pregnancy 1
Postpartum Women 1
Microvascular Function 1
Gestational Diabetes Mellitus (GDM) 1
E-cigarette Use 1

What is open in the Anna Stanhewicz, PhD pipeline

10 recruiting of 14 indexed (71% open); 3 completed (21%).

Phase mix: 0 late (III/IV) vs 14 early (I/II) (early-phase heavy).

Top condition: Gestational Diabetes (4 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Anna Stanhewicz, PhD: open-pipeline peers nationwide

Peers matched on 14 registered trials and 71% open enrollment, not the therapeutic-area sidebar.

Anna Stanhewicz, PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%20%40%60%80% Total trials Recruiting share Anna Stanhewicz, PhD3-C Institute for Social DevelopmentAbbott Medical OpticsAbbott RDx CardiometabolicAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAGlenn J. HannaSenthil SadhasivamCorEvitasRevolution Medicines
Anna Stanhewicz, PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Anna Stanhewicz, PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 14 trials (± recruiting share)

Sponsors near 71% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Anna Stanhewicz, PhD page

14 registered trials is a research-attention snapshot, not an endorsement of Anna Stanhewicz, PhD or any single study.

  • 10 of Anna Stanhewicz, PhD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Gestational Diabetes is the condition Anna Stanhewicz, PhD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gestational Diabetes trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Anna Stanhewicz, PhD pipeline card: 14 registered trials from official public datasets.Report a data error.